EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Peptide-based PET/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma

Yong Wang, Zhiguo Liu, Yang Li, Kelin Wang, Chunhui Yuan, Jian Shi, Jiazhong Ren, Shijie Wang, Jinping Wang, Miaoqing Zhao, Man Hu

Drug Resistance Updates · 2025-03 · 79 · 101202

DOI: 10.1016/j.drup.2025.101202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-03. Verfasst von Yong Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Glioblastoma, B7-H1 Antigen, Positron Emission Tomography Computed Tomography, Radiation Tolerance. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radioresistance remains a great challenge for radiotherapy in the treatment of glioblastoma (GBM). PD-L1 expression is a key contributor to radioresistance and immune escape in GBM. The lack of effective methods to monitor the change of PD-L1 during radiotherapy in patients limits timely intervention and management of the resistance. Here, we developed a novel peptide tracer [18F]AlF-NOTA-PCP2 for PET/CT to visualize the changes of PD-L1 expression in response to radiotherapy, revealing PD-L1-driven radioresistance in GBM. The [18F]AlF-NOTA-PCP2 demonstrated high specificity and binding affinity to PD-L1 in vitro. The uptake of [18F]AlF-NOTA-PCP2 on PET/CT showed a strong positive correlation with PD-L1 expression by immunohistochemistry (IHC) (R² = 0.861, P < 0.001) in GBM xenograft tumors. The radiotracer uptake in PD-L1-positive tumors significantly increased post-radiotherapy (21.25 ± 0.91 % vs. 25.12 ± 0.82 %, P = 0.008), aligning with the radioresistance observed in these tumors. In vitro studies revealed that PD-L1-driven radioresistance by enhancing DNA damage repair through upregulation of RAD51 after activation of the PI3K-Akt pathway in cells. Preliminary clinical application in a radiotherapy-treated GBM patient demonstrated the ability to monitor PD-L1 dynamics, supporting its potential for clinical translation. Collectively, this peptide-based small molecule PET/CT radiotracers offer a noninvasive, real-time, and quantitative method to dynamically visualize PD-L1-driven radioresistance in GBM. It could serve as a potential radiotracer for facilitating patient stratification, adjusting radiotherapy regimens, and guiding personalized immunotherapy strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaB7-H1 AntigenPositron Emission Tomography Computed TomographyRadiation ToleranceBrain NeoplasmsPeptidesHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysRadiopharmaceuticalsFluorine RadioisotopesMice, Nude

Stichwörter der Autor:innen

GlioblastomaPD-L1PET/CTPeptide radiotracerRadioresistance

Substanzen

B7-H1 AntigenCD274 protein, humanRadiopharmaceuticalsFluorine RadioisotopesPeptides

Autor:innen und Institutionen

  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.
  • Department of PET/CT Center, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.
  • Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.
  • Institute of Surface Analysis and Chemical Biology, University of Jinan, Jinan, Shandong 250022, China.
  • Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.
  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China. Electronic address: mhu@sdfmu.edu.cn.

Förderung

  • Natural Science Foundation of Shandong Province
  • National Natural Science Foundation of China

Zitieren

APA

Wang, Y., Liu, Z., Li, Y., Wang, K., Yuan, C., Shi, J., Ren, J., Wang, S., Wang, J., Zhao, M., & Hu, M. (2025). Peptide-based PET/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma. Drug Resistance Updates, 79, 101202. https://doi.org/10.1016/j.drup.2025.101202

Vancouver

Wang Y, Liu Z, Li Y, Wang K, Yuan C, Shi J, et al. Peptide-based PET/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma. Drug Resistance Updates. 2025;79:101202. doi:10.1016/j.drup.2025.101202

BibTeX
@article{Wang2025,
  author = {Wang, Yong and Liu, Zhiguo and Li, Yang and Wang, Kelin and Yuan, Chunhui and Shi, Jian and Ren, Jiazhong and Wang, Shijie and Wang, Jinping and Zhao, Miaoqing and Hu, Man},
  title = {Peptide-based PET/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma},
  journal = {Drug Resistance Updates},
  year = {2025},
  volume = {79},
  pages = {101202},
  doi = {10.1016/j.drup.2025.101202}
}
Kostenlos starten →